# A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer

> **NCT06181266** · PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Prokarium Ltd** · enrollment: 22 (actual)

## Conditions studied

- NMIBC
- High Risk NMIBC
- Non Muscle Invasive Bladder Cancer

## Interventions

- **DRUG:** ZH9

## Key facts

- **NCT ID:** NCT06181266
- **Lead sponsor:** Prokarium Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-01-08
- **Primary completion:** 2025-08-30
- **Final completion:** 2027-07-30
- **Target enrollment:** 22 (ACTUAL)
- **Last updated:** 2025-08-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06181266

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06181266, "A Phase 1/1b Study of ZH9 Treatment in Patients With Non-Muscle Invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT06181266. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*